Alcohol use disorder is a prevalent and major but preventable cause of morbidity and mortality worldwide, causing several important health consequences, including chronic liver disease. Despite its substantial effects, most clinicians do not adequately assess alcohol intake in clinical practice, and there are several barriers to providing integrated management to patients with alcohol use disorder. Standardised questionnaires, such as the Alcohol Use Identification Test (AUDIT), can facilitate the identification of individuals at risk of alcohol use disorder, and alcohol biomarkers such as phosphatidylethanol aid in quantifying levels of alcohol consumption. Non-pharmacological interventions—including brief interventions, twelve-step facilitation, motivational enhancement therapy, contingency management, and cognitive behavioural therapy—are effective for patients with alcohol use disorder, regardless of the presence of advanced liver disease. Pharmacological treatments should be considered according to the severity of liver disease and other comorbidities, safety profile, and local availability. The management of patients with alcohol use disorder and associated liver disease should ideally be performed in the setting of integrated multidisciplinary teams.
Registro Sencillo
Registro Completo
Autor | Díaz Piga, Luis Antonio König, Daniel Weber, Sabine Ayares Campos, Gustavo Ignacio Fuentealba, José Miguel Vázquez, Valeria Bataller, Ramón Kamath, Patrick S. Gerald Scott Winder Leggio, Lorenzo Arab Verdugo, Juan Pablo |
Título | Management of alcohol use disorder: a gastroenterology and hepatology-focused perspective |
Revista | The Lancet Gastroenterology & Hepatology |
ISSN | 2468-1253 |
Fecha de publicación | 2025 |
Resumen | Alcohol use disorder is a prevalent and major but preventable cause of morbidity and mortality worldwide, causing several important health consequences, including chronic liver disease. Despite its substantial effects, most clinicians do not adequately assess alcohol intake in clinical practice, and there are several barriers to providing integrated management to patients with alcohol use disorder. Standardised questionnaires, such as the Alcohol Use Identification Test (AUDIT), can facilitate the identification of individuals at risk of alcohol use disorder, and alcohol biomarkers such as phosphatidylethanol aid in quantifying levels of alcohol consumption. Non-pharmacological interventions—including brief interventions, twelve-step facilitation, motivational enhancement therapy, contingency management, and cognitive behavioural therapy—are effective for patients with alcohol use disorder, regardless of the presence of advanced liver disease. Pharmacological treatments should be considered according to the severity of liver disease and other comorbidities, safety profile, and local availability. The management of patients with alcohol use disorder and associated liver disease should ideally be performed in the setting of integrated multidisciplinary teams. |
Derechos | acceso restringido |
DOI | 10.1016/S2468-1253(24)00380-7 |
Enlace | |
Paginación | 16 páginas |
Temática | Medicina y salud |
Tipo de documento | artículo de revisión |